Sienna Biopharmaceuticals Inc (SNNA) USD0.0001
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.